Access Equity Research

News

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost. 

Access to Exclusive Content. FREE for Registered Users Only. 

Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.

Welcome to the Channelchek Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Inbox Intel from Channelchek.

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2023/04/snal-logo-pr.png" alt="" class="wp-image-62603" style="width:189px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/snal">Research News and Market Data on SNAL</a> 



April 16, 2026 at 4:05 PM EDT



<a href="https://investor.snail.com/node/8746/pdf" target="_blank" rel="noreferrer noopener">PDF Version</a>



<h3 class="wp-block-heading">Company highlights ongoing transition toward a broader multi-platform portfolio supported by new indie releases, expanding partnerships, and long-term AAA development roadmap</h3>



CULVER CITY, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced that&nbsp;<a href="https://www.globenewswire.com/Tracker?data=opNFgfiP02y5Mp7yOVcV0s0Q8ynSXLUWfaCcmiQEDrAf9RWffo9E1PFjbm9w2KJTsqEl6GgAAoElZjsq89DA4o92OKc-PFaEDoTvN4onOfgpyF03Yg_ATE8U2yDWy9zmzHsNP34Rhqpn4NReoIdC3Q==" rel="noreferrer noopener" target="_blank">Survivor Mercs</a>&nbsp;will officially launch its 1.0 version on April 30, 2026. Published under the Company’s indie label, Wandering Wizard, the game will be available on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=k5BpYhswp4hREild1q7lQOik2TTWFLJ2rASZuxSD9QtveNiYmwenn26ImIR4O1_lmOr2SmwsGacc6NRjwVKUu9wYNXJKqCkxQCh_tfXkQc1G_dK8L-k8iiasM0bDeqEl" rel="noreferrer noopener" target="_blank">Steam</a>, Xbox, and&nbsp;<a href="https://www.globenewswire.com/Tracker?data=SjDy5wpfWJf9hR4O3obf7MI0eqsDR60B47ac7tAOkHFC-X2gsHbV_T3-Xll0pWeaZFQzSThyFnFNVAGvqKYNVoiNqQrjLpG59cBjAJ2f3ArlbqDsZnMcQA3Y77i0yuAx" rel="noreferrer noopener" target="_blank">PlayStation</a>, marking its transition from Early Access into a full global release.



Built alongside its community over multiple updates,&nbsp;Survivor Mercs&nbsp;heads into 1.0 with expanded content, refined systems, and a gameplay experience designed to support long-term player engagement. With its debut on consoles, the title has the potential to reach a broader audience, further strengthening Snail Games’ multi-platform presence.



<a href="https://www.globenewswire.com/Tracker?data=eLyZ4CyrwlPfvK6duj_w-Pj7eBbGloU2Hx6ipAo9ce4C_Q6NYJ5vUoBXpj5_41817MeaG0wireVguAOyE-2pzhrRgVUYiKy3ztdOdJ4aKgMmfZcVFRXJfhKU8xdVHjvGimVBc7y89RED60t9fg3bxMVEYdUvt-6qP8UCo9MYiOo=" rel="noreferrer noopener" target="_blank">Watch&nbsp;Survivor Mercs&nbsp;Official Launch Date Announcement Trailer</a>



The release also reflects Wandering Wizard’s growing role within the Company’s publishing strategy. By supporting projects through development and community feedback, the label continues to bring titles to market that are both polished and positioned for long term relevance, supporting a broader shift toward scalable, internally driven growth.



This direction was recently underscored in an&nbsp;<a href="https://www.globenewswire.com/Tracker?data=xIIHDR8WZjOSexF0TuMuJjZfA06VtN2itf4ER0VhRalXJAszbUxnmgv5a-kDg2t54J3nl24WsiyEtmeWDr1c-D2VWMT6wJXwx8snPstGEVWQ4LXjgKoi2YqmoY-LMa9ZvmelOwWnYMMTc89hSqVidZAQQ2rPuLYTHGIZySoiPqckSOJDG4o18VK2oKBxLdYRy3kVPPtTSAb2x0Uns3_nI15HRS2T0YFMgoP2HI0c9_XGcPg9YyFJs44Bik-fqcKKEpppsapuE5KqRnqdd7Wopg==" rel="noreferrer noopener" target="_blank">interview with Proactive Investors</a>, where Snail Games highlighted its strategy forming a growing pipeline of titles. CFO Heidy Chow noted,&nbsp;“We don’t want to rely on just one IP, we want to be more diversified. Our focus is on building a broader portfolio across genres, platforms, and development models to create a more balanced foundation that can support long-term growth.”&nbsp;CFO Chow also highlighted the Company’s recently amended Software License Agreement with SDE Inc., which provides the Company with an exclusive worldwide license to publish and sell&nbsp;ARK: Survival Evolved&nbsp;and&nbsp;ARK Survival Ascended. Under this amended agreement, the annual license fee was reduced by $6 million, with the savings being redirected back into internal development and operations. Snail Games is actively broadening its business beyond the ARK franchise through a diversified slate of indie, mid-core, and AAA experiences.



Progress with this strategy is exemplified by Snail Games seeing encouraging traction across its broader pipeline.&nbsp;<a href="https://www.globenewswire.com/Tracker?data=mJLAy2PIWwu66TiKEvUXtnyzotVwUTsmLPcbkO93ms9Ekc9J38_EWSzI8o2AoOOOqhMVK2OVkQqnNSlkoEZTt3qKuZ8fhSHPjlwFlHeiXxqqXe1tWam0GK5uPMyQPoXPihsnpzzSCoCxgkoksUUcNg==" rel="noreferrer noopener" target="_blank">Echoes of Elysium</a>, an upcoming title currently surpassing 170,000 wishlists, continues to build visibility as it progresses toward its own 1.0 release. Ongoing updates and steady community growth point to strong early interest and reinforce the game’s positioning as a high-potential addition to the Company’s portfolio.



The Company’s expanding pipeline is supported by increased investment in internal development, global studio partnerships, and a continued focus on long-term content creation.&nbsp;<a href="https://www.globenewswire.com/Tracker?data=ExiTHbLqrT2bxOKkgbHevRX-eLc9CSLBGyfnhzs4IKjuX031WXB-PRxuHW0b0QYqLBFRWVaVf4OOCyhHJ-5ZvMc8thQukaLqJ_rS4q5Jj7pxOBWY2MYDVMGokI7A3LaR" rel="noreferrer noopener" target="_blank">Bellwright</a>, developed by Polish studio Donkey Crew, of which Snail Games holds a strategic ownership stake, serves as a clear example of this approach in action. The title surpassed 1 million lifetime downloads earlier this year and continues to see ongoing expansion following its early access launch. It will also be featured in Steam’s Medieval Fest next week, providing additional visibility and further engagement opportunities before its 1.0 release and console port.



This approach extends further into the longer term pipeline, where three internally developed AAA titles are currently in progress for 2027, including&nbsp;<a href="https://www.globenewswire.com/Tracker?data=PkT9SwGRKeowW-nwH5K4GhW0PgYNmxZSIW3p7rcAhw_NC_Tuz-rG3AANqYF5LNYn4pwpgTMq0oIkt210OsOMgfeYvXdtN7dBPzn2jbk5EcDImysmGr0UryMz8PJU4NUGxb1rrJnvWgbqU9RCOzaBeg==" rel="noreferrer noopener" target="_blank">For The Stars</a>. Together, this combination of active releases and future facing development supports a more continuous content cycle designed to expand global reach and build a more diversified and durable portfolio over time.



For content creators interested in collaborations, please reach out to creatordirect@noiz.gg



About Snail, Inc. Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=uQxeFnVTUiBvKKg03B1QBWvb6Yjscfu9dMOHWpMEOgfkqYqXK6zo45TsGRbEhKU8On_IFArTS77aP-gH8SZqvQ==" rel="noreferrer noopener" target="_blank">https://snail.com/</a>



Forward-Looking Statements: This press release contains statements that constitute forward-looking statements within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding officially launching Survivor Mercs in 1.0 on April 30, the game being available on Steam, Xbox, and PlayStation, designing the gameplay experience to support long-term player engagement, the title having the potential to reach a broader audience, further strengthening Snail Games’ multi-platform presence, Wandering Wizard’s growing role within the Company’s publishing strategy, the label continuing to bring titles to market that are both polished and positioned for long term relevance, supporting a broader shift toward scalable, internally driven growth, forming a growing pipeline of titles, being more diversified, building a broader portfolio across genres, platforms, and development models to create a more balanced foundation that can support long-term growth, the deliberate effort to expand across indie, mid-core, and AAA experiences, seeing encouraging traction across the Company’s broader pipeline, Echoes of Elysium continuing to build visibility as it progresses toward its own 1.0 release with its latest update, ongoing updates and steady community growth pointing to strong early interest and reinforcing the game’s positioning as a high-potential addition to the Company’s portfolio, the Company’s expanding pipeline being supported by increased investment in internal development, global studio partnerships, and a continued focus on long-term content creation, Bellwright continuing to see ongoing expansion following its early access launch, Bellwright being featured in Steam’s Medieval Fest next week, providing additional visibility and further engagement opportunities before its 1.0 release and console port, three internally developed AAA titles being currently in progress for 2027, including For The Stars, and the combination of active releases and future facing development supporting a more continuous content cycle designed to expand global reach and build a more diversified and durable portfolio over time. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to build a broader portfolio across genres, platforms, and development models to create a more balanced foundation that can support long-term growth, acceptance of our titles in the marketplace and the successful development, marketing or sale of our titles and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.



Investor Contact: John Yi and Steven Shinmachi Gateway Group, Inc. 949-574-3860 <a href="https://www.globenewswire.com/Tracker?data=DUx1X8kcshQA5H7orbGw8IJhvIdJouXwJzk1rOgP5xf-xpv2QvkdP4WSowZMtdyIN34JcCFGAbOqCq4wvqn7Zo9tWvDSpIdd1W_5s5otX6TMIqqU795XeMewz7KA0B8mi6w4zfoluvs-KVSrQOytRklsel95EJrMjmmw9dQPTxaqIKGWcZODS9u90aKI8axbkWRHgJXL8tsvlQq32qgk62p2443N5zI2t3U0CyQQIDf4UQpdV5lAr1ZfNwV6rAnHY90j7OThGJSLlFpzY_zlvg==" rel="noreferrer noopener" target="_blank">SNAL@gateway-grp.com</a>

Research News and Market Data on SNAL 



April 16, 2026 at 4:05 PM EDT



PDF Version



Company highlights ongoing transition toward a broader multi-platform portfolio supported by new indie releases, expanding partnerships, and long-term AAA development roadmap



CULVER CITY, Calif., April 16, 2026 (GLOBE NEWSWIRE) &#8212; Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced that&nbsp;Survivor Mercs&nbsp;will officially launch its 1.0 version on April 30, 2026. Published under the Company’s indie label, Wandering Wizard, the game will be available on&nbsp;Steam, Xbox, and&nbsp;PlayStation, marking its transition from Early Access into a full global release.



Built alongside its community over multiple updates,&nbsp;Survivor Mercs&nbsp;heads into 1.0 with expanded content, refined systems, and a gameplay experience designed to support long-term player engagement. With its debut on consoles, the title has the potential to reach a broader audience, further strengthening Snail Games’ multi-platform presence.



Watch&nbsp;Survivor Mercs&nbsp;Official Launch Date Announcement Trailer



The release also reflects Wandering Wizard’s growing role within the Company’s publishing strategy. By supporting projects through development and community feedback, the label continues to bring titles to market that are both polished and positioned for long term relevance, supporting a broader shift toward scalable, internally driven growth.



This direction was recently underscored in an&nbsp;interview with Proactive Investors, where Snail Games highlighted its strategy forming a growing pipeline of titles. CFO Heidy Chow noted,&nbsp;“We don’t want to rely on just one IP, we want to be more diversified. Our focus is on building a broader portfolio across genres, platforms, and development models to create a more balanced foundation that can support long-term growth.”&nbsp;CFO Chow also highlighted the Company’s recently amended Software License Agreement with SDE Inc., which provides the Company with an exclusive worldwide license to publish and sell&nbsp;ARK: Survival Evolved&nbsp;and&nbsp;ARK Survival Ascended. Under this amended agreement, the annual license fee was reduced by $6 million, with the savings being redirected back into internal development and operations. Snail Games is actively broadening its business beyond the ARK franchise through a diversified slate of indie, mid-core, and AAA experiences.



Progress with this strategy is exemplified by Snail Games seeing encouraging traction across its broader pipeline.&nbsp;Echoes of Elysium, an upcoming title currently surpassing 170,000 wishlists, continues to build visibility as it progresses toward its own 1.0 release. Ongoing updates and steady community growth point to strong early interest and reinforce the game’s positioning as a high-potential addition to the Company’s portfolio.



The Company’s expanding pipeline is supported by increased investment in internal development, global studio partnerships, and a continued focus on long-term content creation.&nbsp;Bellwright, developed by Polish studio Donkey Crew, of which Snail Games holds a strategic ownership stake, serves as a clear example of this approach in action. The title surpassed 1 million lifetime downloads earlier this year and continues to see ongoing expansion following its early access launch. It will also be featured in Steam’s Medieval Fest next week, providing additional visibility and further engagement opportunities before its 1.0 release and console port.



This approach extends further into the longer term pipeline, where three internally developed AAA titles are currently in progress for 2027, including&nbsp;For The Stars. Together, this combination of active releases and future facing development supports a more continuous content cycle designed to expand global reach and build a more diversified and durable portfolio over time.



For content creators interested in collaborations, please reach out to creatordirect@noiz.gg



About Snail, Inc.Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit:&nbsp;https://snail.com/



Forward-Looking Statements:This press release contains statements that constitute forward-looking statements within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding officially launching Survivor Mercs in 1.0 on April 30, the game being available on Steam, Xbox, and PlayStation, designing the gameplay experience to support long-term player engagement, the title having the potential to reach a broader audience, further strengthening Snail Games’ multi-platform presence, Wandering Wizard’s growing role within the Company’s publishing strategy, the label continuing to bring titles to market that are both polished and positioned for long term relevance, supporting a broader shift toward scalable, internally driven growth, forming a growing pipeline of titles, being more diversified, building a broader portfolio across genres, platforms, and development models to create a more balanced foundation that can support long-term growth, the deliberate effort to expand across indie, mid-core, and AAA experiences, seeing encouraging traction across the Company’s broader pipeline, Echoes of Elysium continuing to build visibility as it progresses toward its own 1.0 release with its latest update, ongoing updates and steady community growth pointing to strong early interest and reinforcing the game’s positioning as a high-potential addition to the Company’s portfolio, the Company’s expanding pipeline being supported by increased investment in internal development, global studio partnerships, and a continued focus on long-term content creation, Bellwright continuing to see ongoing expansion following its early access launch, Bellwright being featured in Steam’s Medieval Fest next week, providing additional visibility and further engagement opportunities before its 1.0 release and console port, three internally developed AAA titles being currently in progress for 2027, including For The Stars, and the combination of active releases and future facing development supporting a more continuous content cycle designed to expand global reach and build a more diversified and durable portfolio over time. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to build a broader portfolio across genres, platforms, and development models to create a more balanced foundation that can support long-term growth, acceptance of our titles in the marketplace and the successful development, marketing or sale of our titles and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.



Investor Contact:John Yi and Steven ShinmachiGateway Group, Inc.949-574-3860SNAL@gateway-grp.com

Release -Snail Games Expands Global Games Pipeline with Upcoming Launches and Long-Term Publishing and Development Diversification Strategy

Media &amp; Entertainment

Snail Inc.

SNAL

Anthropic is expanding its AI model lineup with the release of Claude Opus 4.7, a new offering the company positions as its most capable generally available model to date — while deliberately keeping its most powerful, and potentially most dangerous, technology off the open market.



The San Francisco-based AI firm says Opus 4.7 delivers meaningful improvements over its predecessor, Claude Opus 4.6, across a range of performance benchmarks including agentic coding, multidisciplinary reasoning, scaled tool use and computer use. For enterprise users and developers, the model is designed to handle complex, real-world workflows more effectively — a direct response to the growing demand for AI that can operate with greater autonomy across business processes.



But what makes this launch notable is not just what Claude Opus 4.7 can do — it's what it deliberately cannot.



Anthropic has engineered the new model to have reduced cyber capabilities compared to Claude Mythos Preview, the company's most advanced model, which was rolled out earlier this month to a limited group of companies as part of a new cybersecurity initiative called Project Glasswing. Mythos is not generally available and Anthropic has no near-term plans to change that. The company says it is using Project Glasswing as a controlled environment to study how powerful models behave in real-world cybersecurity contexts before considering any broader release.



With Opus 4.7, Anthropic has embedded safeguards that automatically detect and block requests flagged as prohibited or high-risk cybersecurity uses. The company said it also experimented with training techniques aimed at selectively reducing those capabilities at the model level — not just through filtering after the fact. Security professionals with legitimate use cases can apply through a formal verification program to access those capabilities.



The approach reflects the tightrope Anthropic has walked since its founding in 2021 — building competitive, high-performance AI while maintaining what has become the company's core differentiator: a reputation for safety-first development. That reputation is now being tested at an entirely new scale.



The launch of Project Glasswing has triggered a wave of high-profile conversations across Washington and Wall Street, with members of the Trump administration, tech executives and bank CEOs meeting to assess what Mythos-class AI capabilities could mean for national security and financial infrastructure. The underlying question — how powerful should a publicly available AI model be — is no longer theoretical.



For investors and enterprises, the practical implications of Opus 4.7 are more immediate. The model is priced identically to Opus 4.6, meaning businesses get a material upgrade at no additional cost. It is available across all Anthropic Claude products, its API and through cloud distribution partners Microsoft, Google and Amazon — giving it broad accessibility across the enterprise ecosystem.



The release also signals something important about where the AI industry is heading. Capability tiers are becoming a deliberate strategic tool. The most powerful models are being gated, studied and selectively deployed — not because they aren't ready, but because the institutions using them need to be.



For small and mid-cap technology companies building on top of AI infrastructure, the implications are significant. As foundation model providers like Anthropic establish formal verification programs and tiered access structures, third-party developers and SaaS companies will need to navigate an increasingly credentialed ecosystem — one where access to the most powerful tools requires demonstrating not just technical fit, but responsible use.

Anthropic is expanding its AI model lineup with the release of Claude Opus 4.7, a new offering the company positions as its most capable generally available model to date — while deliberately keeping its most powerful, and potentially most dangerous, technology off the open market.



The San Francisco-based AI firm says Opus 4.7 delivers meaningful improvements over its predecessor, Claude Opus 4.6, across a range of performance benchmarks including agentic coding, multidisciplinary reasoning, scaled tool use and computer use. For enterprise users and developers, the model is designed to handle complex, real-world workflows more effectively — a direct response to the growing demand for AI that can operate with greater autonomy across business processes.



But what makes this launch notable is not just what Claude Opus 4.7 can do — it&#8217;s what it deliberately cannot.



Anthropic has engineered the new model to have reduced cyber capabilities compared to Claude Mythos Preview, the company&#8217;s most advanced model, which was rolled out earlier this month to a limited group of companies as part of a new cybersecurity initiative called Project Glasswing. Mythos is not generally available and Anthropic has no near-term plans to change that. The company says it is using Project Glasswing as a controlled environment to study how powerful models behave in real-world cybersecurity contexts before considering any broader release.



With Opus 4.7, Anthropic has embedded safeguards that automatically detect and block requests flagged as prohibited or high-risk cybersecurity uses. The company said it also experimented with training techniques aimed at selectively reducing those capabilities at the model level — not just through filtering after the fact. Security professionals with legitimate use cases can apply through a formal verification program to access those capabilities.



The approach reflects the tightrope Anthropic has walked since its founding in 2021 — building competitive, high-performance AI while maintaining what has become the company&#8217;s core differentiator: a reputation for safety-first development. That reputation is now being tested at an entirely new scale.



The launch of Project Glasswing has triggered a wave of high-profile conversations across Washington and Wall Street, with members of the Trump administration, tech executives and bank CEOs meeting to assess what Mythos-class AI capabilities could mean for national security and financial infrastructure. The underlying question — how powerful should a publicly available AI model be — is no longer theoretical.



For investors and enterprises, the practical implications of Opus 4.7 are more immediate. The model is priced identically to Opus 4.6, meaning businesses get a material upgrade at no additional cost. It is available across all Anthropic Claude products, its API and through cloud distribution partners Microsoft, Google and Amazon — giving it broad accessibility across the enterprise ecosystem.



The release also signals something important about where the AI industry is heading. Capability tiers are becoming a deliberate strategic tool. The most powerful models are being gated, studied and selectively deployed — not because they aren&#8217;t ready, but because the institutions using them need to be.



For small and mid-cap technology companies building on top of AI infrastructure, the implications are significant. As foundation model providers like Anthropic establish formal verification programs and tiered access structures, third-party developers and SaaS companies will need to navigate an increasingly credentialed ecosystem — one where access to the most powerful tools requires demonstrating not just technical fit, but responsible use.

Anthropic Launches Claude Opus 4.7

Antrhopic

Claude

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2020/10/mrmd_logo.png" alt="" class="wp-image-93709" style="width:128px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/mrmd">Research News and Market Data on MRMD </a>



April 15, 2026 5:00pm EDT <a href="https://d1io3yog0oux5.cloudfront.net/_7a95ffe966b8e0d3c73828183bf79903/marimedadvisors/news/2026-04-15_MariMed_Announces_First_Quarter_2026_Earnings_297.pdf" target="_blank" rel="noreferrer noopener">Download as PDF</a>



NORWOOD, Mass., April 15, 2026 (GLOBE NEWSWIRE) --&nbsp;<a href="https://www.globenewswire.com/Tracker?data=aIkfFbw1VT14qa0A8qpNYa5-Z6Zx1NQavrU4uc2277dPMhXnTLiJgZn-ca1tc1z563HNChI09qodclM6dRZ1SQ==" rel="noreferrer noopener" target="_blank">MariMed Inc</a>. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report its first quarter 2026 financial results on May 13, 2026 after the markets close. Management will host a conference call on May 14, 2026 at 8:00 a.m. EDT to discuss financial results.



A webcast will be available and can be accessed via MariMed’s Investor Relations website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=aIkfFbw1VT14qa0A8qpNYanVh2HslgxAjPfsybakSnqAC-xoSpLIldcA6EllyeKOySGxkW4n1odSajwKRZ3lkjiELSy7B_bRmdGqzq9aACzLtgfK6A1Wvh9O6Z_C9tuJ" rel="noreferrer noopener" target="_blank">MariMed Q1 2026 Earnings Webcast</a>. A playback of the call will also be made available on MariMed’s Investor Relations website.



About MariMed MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including&nbsp;Betty's Eddies™,&nbsp;Bubby’s Baked™,&nbsp;InHouse™,&nbsp;Nature’s Heritage™, and&nbsp;Vibations™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. The Company is also recognized for delivering exceptional customer service at our 13&nbsp;<a href="https://www.globenewswire.com/Tracker?data=x0Opi_bv4xdibLCUlSGtXHlQDNGW0GNKxKsrsHFeN9YQy7nOReSlS-o3Qh7Ycwplqs2EJf9r0wUjzTu0KRh8UKiNkXHTnw0V75vvLkrDG8A=" rel="noreferrer noopener" target="_blank">Thrive Dispensary</a>&nbsp;retail locations across five states. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=mTTbQV5LBT3Yy-QMGLmEwdZz2y_INfYtSfix4x_o-IWrUWjUJk46zUMGTzLoJywI8A2jrKR4z2LawBc8fxsziFy2CpBxptHl6HKX9OYf1zM=" rel="noreferrer noopener" target="_blank">www.marimedinc.com</a>.



Company Contact: Howard Schacter Chief Communications Officer&nbsp; Email:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=JklMMjHcexqNlgMcpR7NVJgOolOvDJUTao8d9bWwWSNNL1ww1ISL7Et2ny-bg8pstQKT-daRi3DtwrDhf2JdZFR1LKQe9f4HLx_RsFXWWDau3jjD0V0a5YPL0CtwA3qD" rel="noreferrer noopener" target="_blank">hschacter@marimedinc.com</a> Phone: (781) 277-0007



<figure class="wp-block-image"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/d78e59da-6797-4331-81fb-187d81a70f06"><img src="https://ml.globenewswire.com/media/d78e59da-6797-4331-81fb-187d81a70f06/small/mrmd-logo-png.png" alt="Primary Logo"/></a></figure>



Source: MariMed Inc.



Released April 15, 2026

Research News and Market Data on MRMD 



April 15, 2026 5:00pm EDT Download as PDF



NORWOOD, Mass., April 15, 2026 (GLOBE NEWSWIRE) &#8212;&nbsp;MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report its first quarter 2026 financial results on May 13, 2026 after the markets close. Management will host a conference call on May 14, 2026 at 8:00 a.m. EDT to discuss financial results.



A webcast will be available and can be accessed via MariMed’s Investor Relations website at&nbsp;MariMed Q1 2026 Earnings Webcast. A playback of the call will also be made available on MariMed’s Investor Relations website.



About MariMedMariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including&nbsp;Betty&#8217;s Eddies™,&nbsp;Bubby’s Baked™,&nbsp;InHouse™,&nbsp;Nature’s Heritage™, and&nbsp;Vibations™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. The Company is also recognized for delivering exceptional customer service at our 13&nbsp;Thrive Dispensary&nbsp;retail locations across five states. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit&nbsp;www.marimedinc.com.



Company Contact:Howard SchacterChief Communications Officer&nbsp;Email:&nbsp;hschacter@marimedinc.comPhone: (781) 277-0007







Source: MariMed Inc.



Released April 15, 2026

Release - MariMed Announces First Quarter 2026 Earnings Date

Cannaabis

MariMed Inc.

MRMD

<figure class="wp-block-image aligncenter is-resized"><img src="https://www.geovax.com/images/GeoVax_logo-bright-blue-v2-315px.png" alt="GeoVax" style="width:235px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/govx">Research News and Market Data on GOVX </a>



<a href="https://www.geovax.com/investors/press-releases/geovax-reports-2025-year-end-financial-results-and-provides-business-update#"></a>



Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine)



Scheduled to Initiate During the Second Half of This Year



ATLANTA, GA, April 15, 2026&nbsp;– GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies against infectious diseases and cancer, today announced its financial results and key operational accomplishments for the year ended December 31, 2025.



“During 2025, we made significant progress advancing GEO-MVA toward late-stage clinical development, supported by regulatory alignment with the European Medicines Agency (EMA) and key manufacturing milestones,” stated David Dodd, Chairman and Chief Executive Officer of GeoVax. "We believe GEO-MVA represents a critically important opportunity to eliminate the current global supply constraint in orthopoxvirus vaccines, while supporting broader public health preparedness and biosecurity objectives. As such, we look forward to initiating the planned Phase 3 immuno-bridging study in the second half of this year, which represents the next key step in advancing GEO-MVA to regulatory approval and access, providing a critically needed supply source of MVA-vaccine.”



Mr. Dodd concluded, “As we look ahead, our priority is executing key GEO-MVA clinical and regulatory milestones, strengthening strategic partnerships, while selectively advancing other programs, addressing critical medical needs worldwide, while maximizing long-term value to shareholders and stakeholders.”



Corporate and Operational Highlights



Priority Program – GEO-MVA



GeoVax’s primary near-term strategic development focus is the advancement of GEO-MVA, its Modified Vaccinia Ankara (MVA)-based vaccine candidate targeting mpox and smallpox. GEO-MVA is the Company’s most advanced program and its most direct path to potential regulatory approval and commercialization. GEO-MVA is being developed on an expedited regulatory pathway to address a documented global supply constraint in orthopoxvirus vaccines, while supporting both public health preparedness and biosecurity needs, including diversification of supply beyond a single foreign manufacture.



During 2025, the Company achieved several key milestones, advancing GEO-MVA toward late-stage development and commercial readiness:&nbsp;



<ul class="wp-block-list">
<li>Regulatory Alignment: GeoVax received formal Scientific Advice from the European Medicines Agency (EMA), supporting a streamlined and accelerated development pathway for GEO-MVA, including a single Phase 3 immuno-bridging study without the need for prior Phase 1 or Phase 2 trials.</li>



<li>Phase 3 Readiness: The Company is preparing to initiate a pivotal Phase 3 clinical trial in the second half of 2026, representing the critical next step toward potential regulatory approval and product distribution.</li>



<li>Manufacturing Progress: GeoVax completed cGMP manufacturing and fill-finish of clinical-grade GEO-MVA, establishing readiness for clinical supply and potential commercialization.</li>
</ul>



GeoVax believes GEO-MVA is uniquely positioned at the intersection of:



<ul class="wp-block-list">
<li>Recurring global mpox outbreaks and evolving viral strains</li>



<li>Depleted government stockpiles following recent outbreaks</li>



<li>Policy-driven demand for diversified and domestic vaccine supply</li>
</ul>



Given these dynamics, GEO-MVA is expected to play a central role in global orthopoxvirus preparedness strategies. The Company is actively aligning GEO-MVA with public health preparedness and biosecurity procurement frameworks, including engagement with international regulatory and governmental stakeholders.



Additional Progress Across Clinical Pipeline



Beyond GEO-MVA, GeoVax continues to advance a diversified pipeline spanning infectious diseases and oncology:



<ul class="wp-block-list">
<li>GEO-CM04S1 (COVID-19 Vaccine):
<ul class="wp-block-list">
<li>Advancing through multiple Phase 2 clinical trials targeting immunocompromised populations, including stem cell transplant and CLL patients.</li>



<li>Data readouts expected in 2026, including from a completed booster trial in healthy adults.</li>



<li>Interim DSMB findings in the CLL study indicated superior immune responses versus mRNA comparator, supporting continued development.</li>
</ul>
</li>



<li>Gedeptin® (Oncology):
<ul class="wp-block-list">
<li>Completed Phase 1/2 clinical evaluation in advanced head and neck cancer.</li>



<li>Entered into an exclusive license agreement with Emory University to support combination use with immune checkpoint inhibitors.</li>



<li>Planning Phase 2 trial for first-line treatment in locally advanced head and neck squamous cell carcinoma (2027).</li>
</ul>
</li>
</ul>



2025 Full Year Financial Results



Net Loss: Net loss for the year ended December 31, 2025, was $21.5 million, or $22.40 per share, as compared to $25.0 million, or $120.46 per share, for the year ended December 31, 2024.



Revenue: For the year ended December 31, 2025, the Company reported $2.5 million of government contract revenues associated with the BARDA/RRPV Project NextGen award, compared to $4.0 million during 2024. In April 2025, GeoVax received notification that BARDA determined to terminate the contract for convenience to the government.



R&amp;D Expenses: Research and development expenses were $18.1 million for 2025, compared to $23.7 million in 2024, with the overall decrease primarily related to discontinued costs associated with termination of the BARDA/RRPV contract, as well as lower costs for the GEO-CM04S1 clinical trials and manufacturing costs associated with the GEO-CM04S1 and Gedeptin programs.



G&amp;A Expenses: General and administrative expenses were $6.0 million for 2025, compared to $5.4 million in 2024, with the overall increase primarily due to higher personnel costs, investor relations consulting and other programmatic expenses, patent costs, and stock-based compensation expense.



Cash Position: GeoVax reported cash balances of $3.1 million on December 31, 2025, as compared to $5.5 on December 31, 2024.



Summarized financial information is attached. Further information is included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.



About GeoVax



GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biosecurity preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax’s broader pipeline includes the development of GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit&nbsp;<a href="http://www.geovax.com/">www.geovax.com</a>.



Forward-Looking Statements



This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.



Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Company Contact:



<a href="mailto:info@geovax.com">info@geovax.com</a>



678-384-7220



Media Contact:



Jessica Starman



<a href="mailto:media@geovax.com">media@geovax.com</a>&nbsp;

Research News and Market Data on GOVX 







Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine)



Scheduled to Initiate During the Second Half of This Year



ATLANTA, GA, April 15, 2026&nbsp;– GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies against infectious diseases and cancer, today announced its financial results and key operational accomplishments for the year ended December 31, 2025.



“During 2025, we made significant progress advancing GEO-MVA toward late-stage clinical development, supported by regulatory alignment with the European Medicines Agency (EMA) and key manufacturing milestones,” stated David Dodd, Chairman and Chief Executive Officer of GeoVax. &#8220;We believe GEO-MVA represents a critically important opportunity to eliminate the current global supply constraint in orthopoxvirus vaccines, while supporting broader public health preparedness and biosecurity objectives. As such, we look forward to initiating the planned Phase 3 immuno-bridging study in the second half of this year, which represents the next key step in advancing GEO-MVA to regulatory approval and access, providing a critically needed supply source of MVA-vaccine.”



Mr. Dodd concluded, “As we look ahead, our priority is executing key GEO-MVA clinical and regulatory milestones, strengthening strategic partnerships, while selectively advancing other programs, addressing critical medical needs worldwide, while maximizing long-term value to shareholders and stakeholders.”



Corporate and Operational Highlights



Priority Program – GEO-MVA



GeoVax’s primary near-term strategic development focus is the advancement of GEO-MVA, its Modified Vaccinia Ankara (MVA)-based vaccine candidate targeting mpox and smallpox. GEO-MVA is the Company’s most advanced program and its most direct path to potential regulatory approval and commercialization. GEO-MVA is being developed on an expedited regulatory pathway to address a documented global supply constraint in orthopoxvirus vaccines, while supporting both public health preparedness and biosecurity needs, including diversification of supply beyond a single foreign manufacture.



During 2025, the Company achieved several key milestones, advancing GEO-MVA toward late-stage development and commercial readiness:&nbsp;




Regulatory Alignment: GeoVax received formal Scientific Advice from the European Medicines Agency (EMA), supporting a streamlined and accelerated development pathway for GEO-MVA, including a single Phase 3 immuno-bridging study without the need for prior Phase 1 or Phase 2 trials.



Phase 3 Readiness: The Company is preparing to initiate a pivotal Phase 3 clinical trial in the second half of 2026, representing the critical next step toward potential regulatory approval and product distribution.



Manufacturing Progress: GeoVax completed cGMP manufacturing and fill-finish of clinical-grade GEO-MVA, establishing readiness for clinical supply and potential commercialization.




GeoVax believes GEO-MVA is uniquely positioned at the intersection of:




Recurring global mpox outbreaks and evolving viral strains



Depleted government stockpiles following recent outbreaks



Policy-driven demand for diversified and domestic vaccine supply




Given these dynamics, GEO-MVA is expected to play a central role in global orthopoxvirus preparedness strategies. The Company is actively aligning GEO-MVA with public health preparedness and biosecurity procurement frameworks, including engagement with international regulatory and governmental stakeholders.



Additional Progress Across Clinical Pipeline



Beyond GEO-MVA, GeoVax continues to advance a diversified pipeline spanning infectious diseases and oncology:




GEO-CM04S1 (COVID-19 Vaccine):

Advancing through multiple Phase 2 clinical trials targeting immunocompromised populations, including stem cell transplant and CLL patients.



Data readouts expected in 2026, including from a completed booster trial in healthy adults.



Interim DSMB findings in the CLL study indicated superior immune responses versus mRNA comparator, supporting continued development.





Gedeptin® (Oncology):

Completed Phase 1/2 clinical evaluation in advanced head and neck cancer.



Entered into an exclusive license agreement with Emory University to support combination use with immune checkpoint inhibitors.



Planning Phase 2 trial for first-line treatment in locally advanced head and neck squamous cell carcinoma (2027).






2025 Full Year Financial Results



Net Loss: Net loss for the year ended December 31, 2025, was $21.5 million, or $22.40 per share, as compared to $25.0 million, or $120.46 per share, for the year ended December 31, 2024.



Revenue: For the year ended December 31, 2025, the Company reported $2.5 million of government contract revenues associated with the BARDA/RRPV Project NextGen award, compared to $4.0 million during 2024. In April 2025, GeoVax received notification that BARDA determined to terminate the contract for convenience to the government.



R&amp;D Expenses: Research and development expenses were $18.1 million for 2025, compared to $23.7 million in 2024, with the overall decrease primarily related to discontinued costs associated with termination of the BARDA/RRPV contract, as well as lower costs for the GEO-CM04S1 clinical trials and manufacturing costs associated with the GEO-CM04S1 and Gedeptin programs.



G&amp;A Expenses: General and administrative expenses were $6.0 million for 2025, compared to $5.4 million in 2024, with the overall increase primarily due to higher personnel costs, investor relations consulting and other programmatic expenses, patent costs, and stock-based compensation expense.



Cash Position: GeoVax reported cash balances of $3.1 million on December 31, 2025, as compared to $5.5 on December 31, 2024.



Summarized financial information is attached. Further information is included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.



About GeoVax



GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biosecurity preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax’s broader pipeline includes the development of GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit&nbsp;www.geovax.com.



Forward-Looking Statements



This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.



Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Company Contact:



info@geovax.com



678-384-7220



Media Contact:



Jessica Starman



media@geovax.com&nbsp;

Release - GeoVax Reports 2025 Year-End Financial Results and Provides Business Update

Biotechnology

GeoVax Labs

GOVX

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/03/iii_logo.png" alt="" class="wp-image-7206" style="width:162px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/iii">Research News and Market Data on III</a>



4/16/2026



Composite ISG AI Index™ up 77% since December 2022 inception



Infrastructure leading the way, up 160%, followed by software, up 53%, and services, up 0.3%



STAMFORD, Conn.--(BUSINESS WIRE)--&nbsp;Information Services Group (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.isg-one.com&amp;esheet=54513434&amp;newsitemid=20260416019018&amp;lan=en-US&amp;anchor=ISG&amp;index=1&amp;md5=ae8bd6a955f82daf3087be135d0812b4">ISG</a>) (Nasdaq:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nasdaq.com%2Fmarket-activity%2Fstocks%2Fiii&amp;esheet=54513434&amp;newsitemid=20260416019018&amp;lan=en-US&amp;anchor=III&amp;index=2&amp;md5=ba05cec39aa0ca29891236493a558a64">III</a>), a global AI-centered technology research and advisory firm, today launched the ISG AI Index™, a first-of-its-kind benchmark that measures how AI is impacting the global technology and business services sector.



<figure class="wp-block-image"><img src="https://mms.businesswire.com/media/20260416019018/en/2776646/4/AI_Index_PR_2026.jpg" alt=""/></figure>



The ISG AI Index is a companion to the ISG Index™, the firm’s longstanding and authoritative source for marketplace intelligence on the global technology and business services industry. Detailed findings of the inaugural ISG AI Index will be presented during ISG’s first-quarter ISG Index&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fisgsmarttalk.isg-one.com%2F1q26&amp;esheet=54513434&amp;newsitemid=20260416019018&amp;lan=en-US&amp;anchor=presentation&amp;index=3&amp;md5=18a42d2f163a81d63703bf1ed4422d3c">presentation</a>&nbsp;today at 9 a.m., U.S. Eastern Time.



“For 94 consecutive quarters, ISG has measured the performance of the global technology services industry through our ISG Index,” said Michael P. Connors, chairman and CEO of ISG. “Our highly respected and trusted barometer has evolved over the years to reflect the seismic changes in our industry, including the advent of cloud-based services. Now, the industry is at a new inflection point. It needs a new way to measure the impact of AI on the broader technology services market. The ISG AI Index is that benchmark.”



The ISG AI Index is pegged to a December 2022 starting point. “We selected this month since it coincides with the November 30, 2022 release date of ChatGPT 3.0 and the start of the current AI era,” said Connors. “From there, we are tracking the impact of AI on technology infrastructure, software and services on an ongoing basis, with initial results through the end of 2025.”



Inaugural Results



The inaugural results of the ISG AI Index show that infrastructure-as-a-service (IaaS) has seen the greatest impact from AI, up 160 percent. Software as-a-service (SaaS) has risen 53 percent while managed services is up only slightly, at 0.3 percent. On a market-weighted basis, the composite ISG AI Index was up 77 percent since inception.



“What we are seeing from the ISG AI Index is that AI is already reshaping the technology services sector, but not evenly,” said Steve Hall, the firm’s chief AI officer who leads both the ISG Index and the new ISG AI Index. “Infrastructure is capturing the first wave of growth, as hyperscalers add data center capacity to meet rising demand. Software is monetizing next, while managed services is still in the build-out phase, and that likely means the bigger services impact is still ahead of us.”



The ISG AI Index measures each of the three market segments through a combination of key performance indicators: revenue, profitability and stock price performance, along with one forward-looking AI indicator unique to each segment.



“For each segment, we picked one indicator that best shows how AI is impacting that part of the market,” Hall said. “In infrastructure, we use capital expenditure, because it tells us how much capacity hyperscalers are building ahead of demand. In software, we use current remaining performance obligations, or cRPO, which is essentially backlog—revenue that’s been sold but not yet recognized, making it one of the best forward-looking indicators of demand. And in services, we use revenue per employee, because it gives us a simple view of productivity—how much output providers are generating from their workforce as AI starts to change how work is done.”



Segment Performance



The clearest signal of AI’s impact on infrastructure services is capital expenditure, which is up 265 percent since the inception of the ISG AI Index. Revenue is up 100 percent, profitability is up 60 percent, and stock performance is up 113 percent.



In software, revenue is up 61 percent, profitability is up 18 percent and stock performance is up 39 percent, with cRPO up 71 percent. “This shows the market is still buying and backlog is still building. The market is simply trying to work out how AI changes pricing, monetization and long-term economics,” Hall said.



While the managed services composite is roughly flat, Hall said the underlying signals show revenue up 8 percent, profitability up 4 percent, stock performance down 36 percent and revenue per employee up nearly 8.5 percent. “What this tells us is that AI has started to improve productivity in services, but that has not yet translated into broad-based monetization or market confidence,” Hall said. “AI is having an impact, but that impact is still in the early stages.”



The next edition of the ISG AI Index, to be published after the second quarter, will include additional market measures: AI sentiment, tracking enterprise signals on demand, pricing, margins and investment priorities, and AI maturity, measuring enterprise readiness, constraints and adoption levels.



Further details about the ISG AI Index and its methodology can be found&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fisg-one.com%2Fresearch%2Fisg-index&amp;esheet=54513434&amp;newsitemid=20260416019018&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=1a3b19b0b2f0025664e8ad556c072ac4">here</a>.



About ISG



<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.isg-one.com%2F&amp;esheet=54513434&amp;newsitemid=20260416019018&amp;lan=en-US&amp;anchor=ISG&amp;index=5&amp;md5=63dea9210025f76c2d3d2fc36fe37f08">ISG</a>&nbsp;(Nasdaq:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nasdaq.com%2Fmarket-activity%2Fstocks%2Fiii&amp;esheet=54513434&amp;newsitemid=20260416019018&amp;lan=en-US&amp;anchor=III&amp;index=6&amp;md5=bbf8fa9928a79b9c490b8c7b3ff431d5">III</a>) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.



<figure class="wp-block-image"><img src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260416019018r1&amp;sid=q4-prod&amp;distro=nx&amp;lang=en" alt=""/></figure>



Source: Information Services Group, Inc.

Research News and Market Data on III



4/16/2026



Composite ISG AI Index™ up 77% since December 2022 inception



Infrastructure leading the way, up 160%, followed by software, up 53%, and services, up 0.3%



STAMFORD, Conn.&#8211;(BUSINESS WIRE)&#8211;&nbsp;Information Services Group (ISG) (Nasdaq:&nbsp;III), a global AI-centered technology research and advisory firm, today launched the ISG AI Index™, a first-of-its-kind benchmark that measures how AI is impacting the global technology and business services sector.







The ISG AI Index is a companion to the ISG Index™, the firm’s longstanding and authoritative source for marketplace intelligence on the global technology and business services industry. Detailed findings of the inaugural ISG AI Index will be presented during ISG’s first-quarter ISG Index&nbsp;presentation&nbsp;today at 9 a.m., U.S. Eastern Time.



“For 94 consecutive quarters, ISG has measured the performance of the global technology services industry through our ISG Index,” said Michael P. Connors, chairman and CEO of ISG. “Our highly respected and trusted barometer has evolved over the years to reflect the seismic changes in our industry, including the advent of cloud-based services. Now, the industry is at a new inflection point. It needs a new way to measure the impact of AI on the broader technology services market. The ISG AI Index is that benchmark.”



The ISG AI Index is pegged to a December 2022 starting point. “We selected this month since it coincides with the November 30, 2022 release date of ChatGPT 3.0 and the start of the current AI era,” said Connors. “From there, we are tracking the impact of AI on technology infrastructure, software and services on an ongoing basis, with initial results through the end of 2025.”



Inaugural Results



The inaugural results of the ISG AI Index show that infrastructure-as-a-service (IaaS) has seen the greatest impact from AI, up 160 percent. Software as-a-service (SaaS) has risen 53 percent while managed services is up only slightly, at 0.3 percent. On a market-weighted basis, the composite ISG AI Index was up 77 percent since inception.



“What we are seeing from the ISG AI Index is that AI is already reshaping the technology services sector, but not evenly,” said Steve Hall, the firm’s chief AI officer who leads both the ISG Index and the new ISG AI Index. “Infrastructure is capturing the first wave of growth, as hyperscalers add data center capacity to meet rising demand. Software is monetizing next, while managed services is still in the build-out phase, and that likely means the bigger services impact is still ahead of us.”



The ISG AI Index measures each of the three market segments through a combination of key performance indicators: revenue, profitability and stock price performance, along with one forward-looking AI indicator unique to each segment.



“For each segment, we picked one indicator that best shows how AI is impacting that part of the market,” Hall said. “In infrastructure, we use capital expenditure, because it tells us how much capacity hyperscalers are building ahead of demand. In software, we use current remaining performance obligations, or cRPO, which is essentially backlog—revenue that’s been sold but not yet recognized, making it one of the best forward-looking indicators of demand. And in services, we use revenue per employee, because it gives us a simple view of productivity—how much output providers are generating from their workforce as AI starts to change how work is done.”



Segment Performance



The clearest signal of AI’s impact on infrastructure services is capital expenditure, which is up 265 percent since the inception of the ISG AI Index. Revenue is up 100 percent, profitability is up 60 percent, and stock performance is up 113 percent.



In software, revenue is up 61 percent, profitability is up 18 percent and stock performance is up 39 percent, with cRPO up 71 percent. “This shows the market is still buying and backlog is still building. The market is simply trying to work out how AI changes pricing, monetization and long-term economics,” Hall said.



While the managed services composite is roughly flat, Hall said the underlying signals show revenue up 8 percent, profitability up 4 percent, stock performance down 36 percent and revenue per employee up nearly 8.5 percent. “What this tells us is that AI has started to improve productivity in services, but that has not yet translated into broad-based monetization or market confidence,” Hall said. “AI is having an impact, but that impact is still in the early stages.”



The next edition of the ISG AI Index, to be published after the second quarter, will include additional market measures: AI sentiment, tracking enterprise signals on demand, pricing, margins and investment priorities, and AI maturity, measuring enterprise readiness, constraints and adoption levels.



Further details about the ISG AI Index and its methodology can be found&nbsp;here.



About ISG



ISG&nbsp;(Nasdaq:&nbsp;III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.







Source: Information Services Group, Inc.

Release - ISG Launches First-of-its-Kind Index to Measure AI’s Impact on Technology Services Sector

Information Service Group

Technology

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/10/maia_logo.png" alt="" class="wp-image-60455" style="width:150px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/maia">Research News and Market Data on MAIA </a>



April 16, 2026 9:20am EDT <a href="https://d1io3yog0oux5.cloudfront.net/_ab664557b00bbaa916cc8662b7ef36db/maiabiotech/news/2026-04-16_MAIA_Biotechnology_Activates_First_U_S_Site_for_173.pdf" target="_blank" rel="noreferrer noopener">Download as PDF</a>



Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks



50,000 advanced NSCLC diagnoses in the U.S. annually



CHICAGO, April 16, 2026 (GLOBE NEWSWIRE) --&nbsp;MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the first U.S. clinical site in its Phase 2 THIO-101 expansion trial of its lead investigational therapy as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).



“We are thrilled to activate the expansion of our Phase 2 THIO-101 trial in the U.S., bringing our novel treatment to our country’s broad underserved NSCLC patient population. Every year, we estimate approximately 50,000 patients resistant to chemo and CPIs alone advance to third-line NSCLC in the U.S. The medical need is extensive,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA.



The trial’s expansion into the U.S. marks a key milestone for MAIA, which is expected to open a significantly larger patient pool for evaluation of ateganosine, a novel dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In addition to the first location, Summit Medical Group in New Jersey, MAIA intends to open four additional sites in U.S. in 2026. The trial is ongoing in Europe and Asia with 44 active sites in 6 countries.



MAIA’s THIO-101 expansion study evaluates ateganosine in heavily pre-treated patients in 3L NSCLC who have previously failed treatment with checkpoint inhibitors (CPIs) and chemotherapy. Two treatment arms are being studied: ateganosine sequenced with cemiplimab (Libtayo®) and ateganosine monotherapy. Third-line treatment evaluation in the U.S. is funded by a prestigious&nbsp;<a href="https://www.globenewswire.com/Tracker?data=xMQh91B13BnM2N45FN90bZSdf1RfhXShy65lCvBkh95bW-8Rw-g6SK5OZwSkmsKwA6nBESkXjAu15jAYBy3WQG55X2VOUcCpOEv3jPPwcwvjP2zo8R62XBURcp2RuEkU2v0ugOwieliYarYZh60Rqvy5QsdECztHhYwiDz5TRJp_qlA-Mo-ZKuR77ofkT-oPedH1M3JAhP67lr_NfrY8_RZxIEy5UgrfKHnL6lJ1kjo=" rel="noreferrer noopener" target="_blank">$2.3 million grant</a>&nbsp;from the National Institutes of Health (NIH).



“The activation of Summit Medical Group as our first U.S. clinical site is a landmark moment for the THIO-101 study. This is expected to further advance ateganosine as a potential best-in-class therapy for third-line NSCLC,” said Matthew Failor, MAIA’s Director of Clinical Operations. “Partnering with a premier institution like Summit should allow us to bring this highly innovative telomere-targeting approach to U.S. patients who have limited options.”



“We are proud to be the first U.S. site to offer patients access to MAIA’s innovative THIO-101 expansion trial and contribute to advancing a promising new treatment strategy in lung cancer,” added Charles J. Kim, M.D., Summit Health oncologist and principal investigator for the THIO-101 trial in New Jersey.



MAIA holds&nbsp;<a href="https://www.globenewswire.com/Tracker?data=49P2QLQ6qj9caPmsj3pTyzkgA5rfgHGJ57-8HrrI_dvhCiqKljgZ6mquxu-K5Q9tKeVOVXACq8L3A3rbLXFqZMRMbmOk8le2J8bBl90blc28sers6wcF6JHbFCjqXG-xo3eSJC9scEabbwo4oV6TnFIcCMELO239WmxyYnvYKIhY5P0FM8pzTuhpXpyjprpSzHbrdEcM0McQDS3EH4v6Ru8FBgA7kt2kTkb5Y1mTUFs=" rel="noreferrer noopener" target="_blank">FDA Fast Track designation</a>&nbsp;for its lead drug targeting advanced NSCLC.&nbsp;The Fast Track process is designed to facilitate development and expedite the review of drugs for serious conditions with no treatment options or limited low-efficacy therapies. If relevant criteria are met during the Fast Track process, a drug is eligible for FDA Accelerated Approval and Priority Review (FDA decision within six months).



In 2025, THIO-101 delivered exceptional efficacy data for MAIA’s lead investigational drug sequenced with a checkpoint inhibitor including disease control, response rates, and survival data well above standard of care benchmarks. MAIA recently reported&nbsp;<a href="https://www.globenewswire.com/Tracker?data=chSy33wiF3wA6uQh22vBovCcurfQvKKqaz9CKux9ZK4NlnSqKviVQyBenAo1VwCpmJRjq-21-55KxtWp67LyB7ScKL98i8noQj1yVu5qOrIuiCOYdWo83KVgCcBG_lB7JfcBciYQd-8s9ucaS_8U_aCI6Ew-YbE5OiBVwtSExJd48Pm26WInWfq2anpR6G9GgWMgFN0TVjj6kyvbepgwMAWVzOQkKvq4cXGkUtYBGdZWFqoQFXd8guLcb4vDCKQS" rel="noreferrer noopener" target="_blank">overall survival (OS) beyond two years</a>&nbsp;for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of the trial. The eight patients include one with survival of 33 months and four with survival over 30 months. The measures of 3L OS beyond 24 months exceed all known benchmarks for advanced NSCLC treatment. The THIO-101 treatment regimen has shown an acceptable safety profile to date in a heavily pre-treated population.



About Ateganosine



Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.



About THIO-101 Phase 2 Clinical Trial



THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.



About MAIA Biotechnology, Inc.



MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=5bzVJALZtOKusN6GUv8ghsPhD8eB1ONfN313CSoZwa77LCmOWTRGlVGIK824psUsM1Blhx40fNSjACRpXR8j8g6loH-VwVTHI_RxwgFj1F8=" rel="noreferrer noopener" target="_blank">www.maiabiotech.com</a>.



Forward Looking Statements



MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.



Investor Relations Contact +1 (872) 270-3518 <a href="https://www.globenewswire.com/Tracker?data=BVaS7-DZdvqB54Yfz4pGZ9ySJPVuCSw37lBrOVsKdPky3QwSprAgABMgp1_5L_ywSKIpGx4WuBs5hHyulX8LRK2tv_-FPJ8g8AtSEgCAVOE=" rel="noreferrer noopener" target="_blank">ir@maiabiotech.com</a>



<figure class="wp-block-image"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/a53747c9-c908-4493-b907-21f72017c02c"><img src="https://ml.globenewswire.com/media/a53747c9-c908-4493-b907-21f72017c02c/small/maia-logo-png-teal-png.png" alt="Primary Logo"/></a></figure>



Source: MAIA Biotechnology, Inc.



Released April 16, 2026

Research News and Market Data on MAIA 



April 16, 2026 9:20am EDT Download as PDF



Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks



50,000 advanced NSCLC diagnoses in the U.S. annually



CHICAGO, April 16, 2026 (GLOBE NEWSWIRE) &#8212;&nbsp;MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the first U.S. clinical site in its Phase 2 THIO-101 expansion trial of its lead investigational therapy as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).



“We are thrilled to activate the expansion of our Phase 2 THIO-101 trial in the U.S., bringing our novel treatment to our country’s broad underserved NSCLC patient population. Every year, we estimate approximately 50,000 patients resistant to chemo and CPIs alone advance to third-line NSCLC in the U.S. The medical need is extensive,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA.



The trial’s expansion into the U.S. marks a key milestone for MAIA, which is expected to open a significantly larger patient pool for evaluation of ateganosine, a novel dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In addition to the first location, Summit Medical Group in New Jersey, MAIA intends to open four additional sites in U.S. in 2026. The trial is ongoing in Europe and Asia with 44 active sites in 6 countries.



MAIA’s THIO-101 expansion study evaluates ateganosine in heavily pre-treated patients in 3L NSCLC who have previously failed treatment with checkpoint inhibitors (CPIs) and chemotherapy. Two treatment arms are being studied: ateganosine sequenced with cemiplimab (Libtayo®) and ateganosine monotherapy. Third-line treatment evaluation in the U.S. is funded by a prestigious&nbsp;$2.3 million grant&nbsp;from the National Institutes of Health (NIH).



“The activation of Summit Medical Group as our first U.S. clinical site is a landmark moment for the THIO-101 study. This is expected to further advance ateganosine as a potential best-in-class therapy for third-line NSCLC,” said Matthew Failor, MAIA’s Director of Clinical Operations. “Partnering with a premier institution like Summit should allow us to bring this highly innovative telomere-targeting approach to U.S. patients who have limited options.”



“We are proud to be the first U.S. site to offer patients access to MAIA’s innovative THIO-101 expansion trial and contribute to advancing a promising new treatment strategy in lung cancer,” added Charles J. Kim, M.D., Summit Health oncologist and principal investigator for the THIO-101 trial in New Jersey.



MAIA holds&nbsp;FDA Fast Track designation&nbsp;for its lead drug targeting advanced NSCLC.&nbsp;The Fast Track process is designed to facilitate development and expedite the review of drugs for serious conditions with no treatment options or limited low-efficacy therapies. If relevant criteria are met during the Fast Track process, a drug is eligible for FDA Accelerated Approval and Priority Review (FDA decision within six months).



In 2025, THIO-101 delivered exceptional efficacy data for MAIA’s lead investigational drug sequenced with a checkpoint inhibitor including disease control, response rates, and survival data well above standard of care benchmarks. MAIA recently reported&nbsp;overall survival (OS) beyond two years&nbsp;for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of the trial. The eight patients include one with survival of 33 months and four with survival over 30 months. The measures of 3L OS beyond 24 months exceed all known benchmarks for advanced NSCLC treatment. The THIO-101 treatment regimen has shown an acceptable safety profile to date in a heavily pre-treated population.



About Ateganosine



Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.



About THIO-101 Phase 2 Clinical Trial



THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.



About MAIA Biotechnology, Inc.



MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit&nbsp;www.maiabiotech.com.



Forward Looking Statements



MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.



Investor Relations Contact+1 (872) 270-3518ir@maiabiotech.com







Source: MAIA Biotechnology, Inc.



Released April 16, 2026

Release - MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

MAIA

MAIA Biotechnology

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, April 16, 2026



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Strong Q4 caps solid year.&nbsp;Vince delivered Q4 revenue growth of 4.7% to $83.7 million, with DTC up over 10%, and profitability exceeding the high end of guidance despite a ~$2M Saks-related headwind. Adj. EBITDA exceeded our expectations at $4.5 million versus our $2.0 million estimate.&nbsp;This performance underscores the company’s ability to execute effectively even amid wholesale channel disruption and macro uncertainty.



DTC strength and pricing power drive results.&nbsp;Growth was fueled by robust full-price demand, improved customer experience, and successful pricing actions that offset tariff and freight pressures while maintaining unit volumes. Importantly, this signals a structurally higher-quality revenue base with less reliance on promotions.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/28206">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, April 16, 2026



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Strong Q4 caps solid year.&nbsp;Vince delivered Q4 revenue growth of 4.7% to $83.7 million, with DTC up over 10%, and profitability exceeding the high end of guidance despite a ~$2M Saks-related headwind. Adj. EBITDA exceeded our expectations at $4.5 million versus our $2.0 million estimate.&nbsp;This performance underscores the company’s ability to execute effectively even amid wholesale channel disruption and macro uncertainty.



DTC strength and pricing power drive results.&nbsp;Growth was fueled by robust full-price demand, improved customer experience, and successful pricing actions that offset tariff and freight pressures while maintaining unit volumes. Importantly, this signals a structurally higher-quality revenue base with less reliance on promotions.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Vince Holding Corp. (VNCE) - Operating Execution Driving EBITDA Upside

Fashion

Retail

Vince Holding

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, April 16, 2026



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Continued drilling success in the Lion Zone.&nbsp;Recent Winter 2026 drill results further defined the high-grade Lion Zone ahead of a planned 2026 Mineral Resource Estimate (MRE) for the Nisk project that will incorporate Lion Zone mineralization. Infill drilling confirmed continuity of mineralization, highlighted by notable intercepts, including 4.76 meters grading 10.43% copper equivalent (CuEq) and 4.35 meters at 5.94% CuEq, along with broad intervals including 27.1 meters at 2.17% CuEq. These results reinforce confidence in the geological model and support potential resources in the Indicated category.



Near-surface drilling reinforces development potential.&nbsp;Shallow drilling continues to demonstrate strong near-surface mineralization that may be suitable for open-pit extraction, enhancing the project’s development potential. Additional noteworthy results, including 3.10 meters at 5.38% CuEq, further validate the presence of consistent high-grade zones that could underpin future economic studies, including a preliminary economic assessment (PEA).



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/28207">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, April 16, 2026



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Continued drilling success in the Lion Zone.&nbsp;Recent Winter 2026 drill results further defined the high-grade Lion Zone ahead of a planned 2026 Mineral Resource Estimate (MRE) for the Nisk project that will incorporate Lion Zone mineralization. Infill drilling confirmed continuity of mineralization, highlighted by notable intercepts, including 4.76 meters grading 10.43% copper equivalent (CuEq) and 4.35 meters at 5.94% CuEq, along with broad intervals including 27.1 meters at 2.17% CuEq. These results reinforce confidence in the geological model and support potential resources in the Indicated category.



Near-surface drilling reinforces development potential.&nbsp;Shallow drilling continues to demonstrate strong near-surface mineralization that may be suitable for open-pit extraction, enhancing the project’s development potential. Additional noteworthy results, including 3.10 meters at 5.38% CuEq, further validate the presence of consistent high-grade zones that could underpin future economic studies, including a preliminary economic assessment (PEA).



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Power Metallic Mines Inc. (PNPNF) - Lion Zone Momentum Builds

Mining

PNPNF

Power Metallic Mines

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, April 16, 2026



Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Investment.&nbsp;Yesterday, Graham announced the sale of $50 million of GHM common stock to certain accounts advised by T. Rowe Price Investment Management, Inc.&nbsp;Graham intends to use proceeds from the stock sale to further strengthen the Company’s balance sheet and financial flexibility through debt repayment and help fund future investment in organic and inorganic growth opportunities.



Details.&nbsp;The T. Rowe Price accounts will acquire 599,808 shares, approximately 5% of the outstanding common, of Graham common stock at $83.36 per share, based upon the 20-day average closing price of the company’s common stock on the New York Stock Exchange on April 13, 2026. The transaction is expected to close on April 16, 2026. The T. Rowe accounts will become the fourth largest shareholder following completion of the transaction. The shares will be registered for resale on a registration statement to be filed with the Securities and Exchange Commission within 30 days.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/28203">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, April 16, 2026



Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Investment.&nbsp;Yesterday, Graham announced the sale of $50 million of GHM common stock to certain accounts advised by T. Rowe Price Investment Management, Inc.&nbsp;Graham intends to use proceeds from the stock sale to further strengthen the Company’s balance sheet and financial flexibility through debt repayment and help fund future investment in organic and inorganic growth opportunities.



Details.&nbsp;The T. Rowe Price accounts will acquire 599,808 shares, approximately 5% of the outstanding common, of Graham common stock at $83.36 per share, based upon the 20-day average closing price of the company’s common stock on the New York Stock Exchange on April 13, 2026. The transaction is expected to close on April 16, 2026. The T. Rowe accounts will become the fourth largest shareholder following completion of the transaction. The shares will be registered for resale on a registration statement to be filed with the Securities and Exchange Commission within 30 days.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Graham (GHM) - Accounts Advised by T. Rowe Price to Invest $50 Million in Graham

Graham

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, April 16, 2026



Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Incremental Term Loan.&nbsp;CoreCivic obtained an incremental term loan in the amount of $100&nbsp;million from existing lenders under its credit facility. The Company expects to use the $100 million to pay down a portion of the amounts outstanding under its revolver and for working capital and general corporate purposes. With the DHS funding issues, we suspect the federal government has been slow in payment, likely resulting in elevated A/R for CoreCivic.



Updated Debt Details.&nbsp;Following the transaction, CoreCivic's Amended Credit Facility is in the aggregate principal amount of $800&nbsp;million, consisting of a $125&nbsp;million initial term loan, the incremental term loan, and a $575&nbsp;million revolving credit facility, which has a $25&nbsp;million sublimit for swingline loans and a $100&nbsp;million sublimit for the issuance of standby letters of credit.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/28204">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, April 16, 2026



Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Incremental Term Loan.&nbsp;CoreCivic obtained an incremental term loan in the amount of $100&nbsp;million from existing lenders under its credit facility. The Company expects to use the $100 million to pay down a portion of the amounts outstanding under its revolver and for working capital and general corporate purposes. With the DHS funding issues, we suspect the federal government has been slow in payment, likely resulting in elevated A/R for CoreCivic.



Updated Debt Details.&nbsp;Following the transaction, CoreCivic&#8217;s Amended Credit Facility is in the aggregate principal amount of $800&nbsp;million, consisting of a $125&nbsp;million initial term loan, the incremental term loan, and a $575&nbsp;million revolving credit facility, which has a $25&nbsp;million sublimit for swingline loans and a $100&nbsp;million sublimit for the issuance of standby letters of credit.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

CoreCivic, Inc. (CXW) - Additional Flexibility

CoreCivic

Detention

Footer menu

Contact Me

Feedback

Test form

Event Registration

The NobleCon20 VIP Giveaway

Noble Announcement | 2H 2025 Events

CFA SOCIETA SARASOTA

Main menu

The NobleCon20 VIP Giveaway – Terms and Conditions
1. Organizer The NobleCon20 VIP Giveaway (“Contest”) is organized by Noble Financial Group and Channelchek (“Organizers”).
2. Eligibility The Contest is open to legal residents of the United States who are 18 years of age or older at the time of entry. Employees of the Organizers, their affiliates, subsidiaries, advertising and promotion agencies, and immediate family members are not eligible to participate.
3. Contest Period The Contest begins on [Start Date] and ends on October 31, 2024, at 11:59 PM ET. Entries submitted after the Contest Period will not be considered.
4. How to Enter To enter the Contest:
<ul>
<li>You must be a registered and verified Channelchek member.</li>
<li>You must complete the Contest entry form available at [Entry Form URL].</li>
</ul>
5. Prize The prize package includes:
<ul>
<li>Round-trip economy airfare for two (2) to South Florida to attend NobleCon20.</li>
<li>Two (2) hotel rooms for the duration of NobleCon20.</li>
<li>Two (2) tickets to NobleCon20, including access to all official NobleCon20 events.</li>
<li>Two (2) VIP meet-and-greet upgrades to the headline event featuring three (3) of the Sharks from ABC’s Shark Tank.</li>
</ul>
There will be one (1) winner chosen. All travel and accommodations are subject to availability and must be arranged through the Organizers. No substitution, transfer, or cash equivalent of prizes is permitted.
6. Winner Selection The winner will be selected on November 1, 2024. The winner will be notified via email using the contact information provided during entry. If the winner does not respond within seven (7) days of the notification, the Organizers reserve the right to select an alternate winner.
7. General Conditions
<ul>
<li>No purchase is necessary to enter or win.</li>
<li>The Contest is void where prohibited by law.</li>
<li>The prize does not include a presentation slot at NobleCon20.</li>
<li>By participating, entrants agree to be bound by these Terms and Conditions and the decisions of the Organizers, which are final and binding in all respects.</li>
<li>The Organizers reserve the right to disqualify any entry that is incomplete, misdirected, or in violation of these Terms and Conditions.</li>
</ul>
8. Privacy By entering the Contest, you agree that your personal information may be used by the Organizers in accordance with their privacy policies.
9. Limitation of Liability The Organizers are not responsible for any incorrect or inaccurate information, technical failures, or unauthorized intervention in the Contest. The Organizers are not liable for any injury or damage to persons or property resulting from participation in the Contest or acceptance or use of any prize.
10. Contact Information For questions or further information about the Contest, please contact the Organizers at contact@channelchek.com.

NobleCon20 VIP Contest Terms

NobleCon20 VIP Giveaway

Show form on click button

<h3 style="text-align: center;">Enjoying Channelchek?</h3>
There&#8217;s more to explore!
<a href="https://www.channelchek.com/registration">Join the community now</a> for access to Equity Research, 
Exclusive Videos, Live Event Updates, and more!
It&#8217;s absolutely free to join.
<a href="https://www.channelchek.com/registration"><img loading="lazy" decoding="async" class=" wp-image-64177 aligncenter" src="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg" alt="" width="351" height="301" /></a>
<script id="xverse-wallet-provider" src="chrome-extension://idnnbdplmphpflfnlkomgpfbpcgelopg/inpage.js"></script>